MorphoSys Competitors
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts | Market Cap |
|---|---|---|---|---|---|---|---|---|
| NOVN | Novartis | Hold |
10
|
CHF89.05 | CHF105.00 | 20.85% | 9 | CHF181.70B |
| ROG | Roche Holding | Hold |
16
|
CHF220.60 | CHF307.83 | 23.53% | 9 | CHF178.03B |
| BMY | Bristol-Myers Squibb | Hold |
2
|
$44.21 | $58.15 | 22.14% | 10 | $89.62B |
| ARGX | argenx | Outperform |
4
|
350.80€ | 531.81€ | 24.86% | 10 | 20.83€B |
| INCY | Incyte | Outperform |
9
|
$52.94 | $77.05 | 45.83% | 8 | $11.89B |
| REC | Recordati Industria Chimica e ... | Hold |
18
|
50.05€ | 48.61€ | 2.80% | 1 | 10.30€B |
| ZEAL | Zealand Pharma A/S | Outperform |
8
|
kr630.00 | kr357.00 | 29.37% | 2 | kr39.42B |
| ORNBV | Orion Oyj | Hold |
14
|
35.79€ | 42.52€ | 17.35% | 3 | 5.04€B |
| HIK | Hikma Pharmaceuticals PLC | Outperform |
18
|
£19.35 | £28.11 | 50.96% | 9 | £4.27B |
| ALK B | ALK-Abelló A/S | Outperform |
13
|
kr131.20 | kr109.25 | 1.37% | 3 | kr28.87B |
| INDV | Indivior PLC | Buy |
14
|
£14.28 | £28.89 | 118.77% | 4 | £1.95B |
| ALM | Almirall | Outperform |
16
|
8.57€ | 11.39€ | 28.35% | 3 | 1.79€B |
| XNCR | Xencor | Outperform |
6
|
$23.93 | $37.91 | 42.08% | 4 | $1.29B |
| COPN | Cosmo Pharmaceuticals N.V. | Buy |
12
|
CHF72.30 | CHF76.55 | 29.41% | 0 | CHF1.16B |
| FAE | Faes Farma | Hold |
18
|
3.41€ | 3.90€ | 7.04% | 0 | 1.06€B |
| PHM | Pharma Mar | Outperform |
13
|
30.44€ | 50.20€ | 57.69% | 1 | 536.95€M |
| BSLN | Basilea Pharmaceutica | Outperform |
6
|
CHF39.50 | CHF65.63 | 67.09% | 0 | CHF474.13M |
| KPTI | Karyopharm Therapeutics | Outperform |
6
|
$1.08 | $6.00 | 362.96% | 1 | $134.63M |
| DBV | DBV Technologies | Outperform |
5
|
1.24€ | 4.07€ | 222.58% | 1 | 119.30€M |
| MOLN | Molecular Partners | Outperform |
4
|
CHF3.29 | CHF9.50 | 184.19% | 1 | CHF110.77M |